The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | D | Dermatologicals | |
2 | D05 | Antipsoriatics | |
3 | D05A | Antipsoriatics for topical use | |
4 | D05AX | Other antipsoriatics for topical use |
Code | Title | |
---|---|---|
D05AX01 | Fumaric acid | |
D05AX02 | Calcipotriol | |
D05AX03 | Calcitriol | |
D05AX04 | Tacalcitol | |
D05AX05 | Tazarotene | |
D05AX06 | ||
D05AX07 | ||
D05AX52 | Calcipotriol, combinations | |
D05AX55 |
Active Ingredient | Description | |
---|---|---|
Calcipotriol |
Calcipotriol is a derivative of vitamin D for topical use on psoriasis. It probably works by suppressing keratinization. Advantage of substance or absence of odor and non-coloring of clothing. |
|
Calcitriol |
Calcitriol is the most active known form of vitamin D3 in stimulating intestinal calcium transport. In physiological amounts it augments the intestinal absorption of calcium and phosphate and plays a significant part in the regulation of bone mineralisation. |
|
Roflumilast |
Roflumilast is a PDE4 inhibitor, a non-steroid, anti-inflammatory active substance designed to target both the systemic and pulmonary inflammation associated with COPD. |
|
Tacalcitol |
Tacalcitol is a vitamin D3 derivative, which inhibits keratinocyte hyper-proliferation and induces differentiation of these cells. The normalisation of these mechanisms is the basis for the efficacy in the treatment of psoriasis. |
|
Tapinarof |
Tapinarof is an aryl hydrocarbon receptor (AhR) agonist. The specific mechanisms by which tapinarof cream exerts its therapeutic action in psoriasis patients are unknown. |
|
Tazarotene |
Tazarotene, a member of the acetylenic class of retinoids, is a prodrug which is converted to its active free form, tazarotenic acid, by de-esterification in the skin area. Tazarotenic acid is the only known metabolite of tazarotene to have retinoid activity. |
Title | Information Source | Document Type | |
---|---|---|---|
CALCIPOTRIOL Cutaneous solution | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
CURATODERM Ointment | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
DAIVOBET Gel | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
DAIVONEX Ointment | Medicines and Medical Devices Safety Authority (NZ) | MPI, EU: SmPC | |
DOVOBET Gel | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
Dovonex Ointment | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
ENSTILAR Foam | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
SILKIS Ointment | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
TAZORAC Cream | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
TAZORAC Gel | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
VTAMA Cream | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
ZORAC Gel | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |